VEGF multispecifics get innovative at AACR 2025

As the industry awaits results from the global Phase III study of ivonescimab, Chinese biotechs have been expanding on the VEGF bispecific concept, exploring alternative designs that could further boost efficacy in solid tumors. At AACR 2025, at least 13 companies are presenting bispecific constructs that move beyond me-too therapies, aiming for greater differentiation.

Abstracts released ahead of the 2025 American Association for Cancer Research (AACR) meeting describe a new wave of VEGF bispecifics featuring alternative VEGF receptor binding domains, novel second targets, and trispecific formats that test whether three targets outperform two...